Compare FuelCell Energy Inc (FCEL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Summit Therapeutics Inc — how do they compare? FuelCell Energy Inc trades at $17.25 (market cap $1.47B), while Summit Therapeutics Inc trades at $17.38 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 9.3× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is more actively traded (12,559,948 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Summit Therapeutics Inc for 16 Days on average.
| FCEL | SMMT | |
|---|---|---|
Market Cap | $1.47B | $13.71B |
Volume | 12,559,948 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $36.01 | $26.38 |
52-Week Low | $6.00 | $12.43 |
Typical Hold Time | 48 Days | 16 Days |
Enterprise Value | $1.05B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $17.29, down 5.85% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported revenue of $158.16M for 2025 but posted a net loss of $187.90M, with negative gross and net income margins. Recent news highlights a securities class action lawsuit and a 7% stock rally amid hydrogen sector interest.
The outlook remains cautious due to persistent losses and legal risks, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include profitability challenges and competitive pressures in the clean energy sector, while potential upside hinges on execution improvements and sector momentum.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
